41 Views Microbiome contract manufacturing Market, Forecast to 2030 posted by Rootsanalysis | Wednesday, August 5, 2020 Category: Pharmacy, Drug & Vitamin Stores Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs. The USD 300 million (by 2030) financial opportunity within the microbiome contract manufacturing market has been analysed across the following segments: Type of Product Manufactured Active Pharmaceutical Ingredients (APIs) Finish Drug Formulations (FDFs) Type of Type of Formulation Solid Formulations Oral Liquids Injectables Others Scale of Operation Clinical Commercial Company Size Small-sized Mid-sized Large Key Geographical Regions North America Europe Asia-Pacific and Rest of the World The Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: Bristol Myers Squibb GlaxoSmithKline Incyte Novartis Trillium Therapeutics Table of Contents Preface Details
33 Views Contract Manufacturing Market Size, Share, Trend & Growth Forecast to 2030 posted by Rootsanalysis | Monday, August 3, 2020 Category: Pharmacy, Drug & Vitamin Stores Roots Analysis has done a detailed study on Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights The microbiome therapies pipeline features 260 drugs under evaluation across different phases of development; contract service providers have become an integral part of the supply chain owing to their technical expertise. Presently, over 25 firms across the globe claim to possess the required know-how and infrastructure to offer contract manufacturing services for live biotherapeutic products and microbiome therapies The market is fragmented, featuring the presence of established players and mid-sized firms across different global regions, with capabilities to manufacture aerobic and / or anaerobic strains, at varying scales of operation Most of the installed, global live biotherapeutic contract manufacturing capacity presently belongs to dedicated Details
31 Views Global Bispecific Antibody Therapeutics Market Report Forecast by Development, Trends, and Forecast (2019 – 2030) posted by Rootsanalysis | Friday, July 31, 2020 Category: Pharmacy, Drug & Vitamin Stores Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights With two approved drugs and close to 300 clinical / preclinical product candidates, the bispecific antibody therapeutics pipeline has evolved significantly over the past few years The pipeline features drug candidates that target a wide range of biological antigens based on different antibody formats through novel mechanisms of action; more than 50% of these act by retargeting or activation of T-Cells To gain a competitive edge in the market, developers are actively exploring novel biological targets and mechanisms of action to treat diverse disease indications Although start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also actively engaged In order to cater to the evolving needs of developers, technology providers have established presence across Details
